Skip to main content
HR 4010 116th Congress House Health Accounting and auditing Business ethics Business records Competition and antitrust Congressional oversight Digestive and metabolic diseases Government information and archives Health care costs and insurance Health care coverage and access Health information and medical records Health programs administration and funding Health technology, devices, supplies Indian social and development programs Inflation and prices Intergovernmental relations Licensing and registrations Manufacturing Minority health Performance measurement

Emergency Access to Insulin Act of 2019

Introduced: July 25, 2019 Introduced by: Craig, Angie Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 26, 2019
Referred to the Subcommittee on Health.
Jul 25, 2019
Referred to the Subcommittee on Health.
Jul 25, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Jul 25, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Emergency Access to Insulin Act of 2019

This bill reduces the marketing exclusivity period for biological drug products from 12 to 7 years and establishes policies and programs designed to increase access to prescription insulin. Specifically, the bill requires the Centers for Disease Control and Prevention to award grants to states to create insulin card programs, which provide uninsured or underinsured individuals with insulin at no cost for specified time periods. Payments for insulin prescriptions made through the program must count toward an underinsured individual’s health plan deductible. Further, the Department of Health and Human Services (HHS) must collect annual fees from insulin manufacturers, based on each manufacturer’s market share, equal to the total estimated expenditures under the insulin grants program.

Subject to certain exceptions, the bill also establishes an excise tax on insulin manufacturers when the price of an insulin product spikes. The tax amount is a specified percentage of the revenue a manufacturer received as a result of the price spike. The tax amount increases in tiers based on the percentage of the price spike for that product.

What's happening now July 26, 2019

Referred to the Subcommittee on Health.

 Related & companion bills 1
  • S 2004 Identical bill Emergency Access to Insulin Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4010: Emergency Access to Insulin Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-4010/
MLA
"H.R. 4010: Emergency Access to Insulin Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-4010/.
Bluebook (legal)
H.R. 4010, 116th Cong. (2026), https://openamerica.io/bill/116-HR-4010/.
Markdown link
[H.R. 4010: Emergency Access to Insulin Act of 2019](https://openamerica.io/bill/116-HR-4010/)
Report a problem